RBD-1016
- Generic Name
- RBD-1016
Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of RBD1016 in Participants With Chronic Hepatitis D
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Ribocure Pharmaceuticals AB
- Target Recruit Count
- 15
- Registration Number
- NCT06649266
- Locations
- 🇸🇪
Infektionskliniken, Danderyds sjukhus, Stockholm, Sweden
🇸🇪Medicinsk enhet för Infektionssjukdomar, Karolinska Universitetssjukhuset Huddinge, Stockholm, Sweden
A Study of RBD1016 in CHB Participants
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Suzhou Ribo Life Science Co. Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT05961098
- Locations
- 🇨🇳
Prince of Wales Hospital, Hong Kong, China
🇨🇳Queen Mary Hospital, Hong Kong, China
🇸🇪Karolinska University Hospital, Stockholm, Sweden
A Single and Repeated Dose Escalation of RBD1016 in Subjects with Chronic Hepatitis B Virus (HBV) Infection
- First Posted Date
- 2021-08-23
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Suzhou Ribo Life Science Co. Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT05017116
- Locations
- 🇨🇳
The University of Hong Kong, Hong Kong, China
A Single Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of RBD1016
- First Posted Date
- 2020-12-28
- Last Posted Date
- 2022-04-26
- Lead Sponsor
- Suzhou Ribo Life Science Co. Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT04685564
- Locations
- 🇦🇺
Scientia Clinical Research Ltd, Randwick, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath